Testing a pre-specified null hypothesis for the primary endpoint at the pre-planned final analysis time sometimes does not tell the whole story. Sponsors, FDA reviewers, members of data monitoring committees and FDA advisory committees sometimes must interpret unexpected outcomes of secondary endpoints at unplanned times. I will provide examples of when I have been in this situation and describe the methods I used to arrive at an interpretation.